Today on Pharmaceutical Processing
UK puts vaccine manufacturing plant up for auction
The U.K. government has put a manufacturing plant up for sale that was instrumental in the country’s plan to battle future pandemics. According to The Financial Times, the plant, dubbed the Vaccine Manufacturing Innovation Centre (VMIC), had received at least £215 million of public funding since it was launched in 2018. A handful of companies…
Pfizer bolsters COVID-19 antiviral manufacturing capacity
Although Pfizer (NYSE:PFE) has yet to receive emergency use authorization for its Paxlovid COVID-19 therapy, it plans to manufacture 80 million courses of the drug by the end of 2022. Pfizer had initially planned on making 50 million courses of Paxlovid (PF-07321332/ritonavir) in the same time frame. An interim analysis of the Phase 2/3 EPIC-HR…
Sponsored Content See More >
Noble expands its services for its clients into Human FactorsHuman Factors + (HF+) is a natural extension of Noble’s deep understanding of the patient experience relative to self-administering drug…
Regulatory See More >
Novo Nordisk settles U.S. securities class action suit
Novo Nordisk (NYSE:NVO) has agreed in principle to settle securities class action litigation in the Federal District Court of New Jersey. The Bagsværd, Denmark–based company would pay $100 million in the settlement. That amount includes plaintiffs’ attorneys’ fees, expenses and settlement costs. The lawsuit alleged that the company made misleading statements regarding the price of its…
Facility See More >
UK puts vaccine manufacturing plant up for auction
The U.K. government has put a manufacturing plant up for sale that was instrumental in the country’s plan to battle future pandemics. According to The Financial Times, the plant, dubbed the Vaccine Manufacturing Innovation Centre (VMIC), had received at least £215 million of public funding since it was launched in 2018. A handful of companies…
Supply Chain See More >
Lessons in life or death logistics
The cell and gene therapy market continues to advance, thanks to its potential to treat cancers and other severe diseases. While the pandemic has had a negative impact on companies specializing in cell and gene therapies, it has also catalyzed interest in cold-chain logistics while highlighting the promise of new therapy types. Organizations interested in…
Recalls See More >
Gilead identifies counterfeit versions of two of its HIV drugs
Gilead Sciences (NSDQ: GILD) has announced that it has identified tampered and counterfeit versions of its HIV drugs Biktarvy and Descovy in the U.S. supply chain. Biktarvy is a blockbuster drug cocktail, raking up $7.26 billion in sales last year. 2020 sales of Descovy were $478 million. Foster City, Calif.–based Gilead said that unauthorized distributors…
